Difference between revisions of "Team:UCSC/Project"

 
(306 intermediate revisions by 3 users not shown)
Line 1: Line 1:
 
{{UCSC-Header}}
 
{{UCSC-Header}}
−
 
 
<html>
 
<html>
 +
<style>
  
−
<style>
+
.metabolic-pathway {
−
.pageflow {
+
   margin: auto;
−
   margin-right: 0px;
+
−
  margin-left: 0px;
+
−
  margin-top:30px;
+
 
   background: honeydew;
 
   background: honeydew;
 +
  width: 100%;
 
}
 
}
  
 
h1 {
 
h1 {
−
   font-family: 'Quicksand' !important;
+
   font-family: 'objektiv-mk1'!important;
 +
  font-size: 300%; /*!important*/
 +
  font-weight: 300 !important;
 +
    width: 90%;
 
}
 
}
  
−
#page {
+
h2 {
−
   background: honeydew;
+
   font-family: 'objektiv-mk1' !important;
 +
  font-size: 200%;
 +
  font-weight: 300;
 
}
 
}
  
−
/* .proj-button {
+
h3 {
−
opacity: 0.6;
+
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 120%;
 +
  font-weight: 200;
 
}
 
}
  
−
.proj-button:hover {
+
#page {
−
opacity: 1;
+
  background: honeydew;
 
}
 
}
−
 
−
.proj-button-desc {
 
−
width: auto;
 
−
height: auto;
 
−
background-color: black;
 
−
opacity: 0.5;
 
−
display: inline-block;
 
−
}
 
−
 
−
*/
 
−
 
  
 
.proj-button {
 
.proj-button {
 
     position: relative;
 
     position: relative;
−
     width: 10%;
+
     width: 25%;
 +
    text-decoration: none !important;
 
}
 
}
  
Line 46: Line 41:
 
   opacity: 1;
 
   opacity: 1;
 
   display: inline-block;
 
   display: inline-block;
−
   width: 16%;
+
   width: 19%;
 +
  height: auto;
 +
  transition: .5s ease;
 +
  backface-visibility: hidden;
 +
}
 +
 
 +
.proj-button-image-solo {
 +
  opacity: 1;
 +
  display: inline-block;
 +
  width: 65%;
 
   height: auto;
 
   height: auto;
 
   transition: .5s ease;
 
   transition: .5s ease;
Line 58: Line 62:
 
   top: 100%;
 
   top: 100%;
 
   left: 50%;
 
   left: 50%;
 +
  background: transparent;
 
   transform: translate(-50%, -50%);
 
   transform: translate(-50%, -50%);
 
   -ms-transform: translate(-50%, -50%)
 
   -ms-transform: translate(-50%, -50%)
 +
}
 +
 +
.overlap-button-text {
 +
  background-color: transparent;
 +
  color: black;
 +
  font-size: 20px;
 +
  font-family: "Objektiv-mk1" !important;
 +
  font-weight: 400 !important;
 +
  padding: 16px 32px;
 
}
 
}
  
 
.proj-button:hover .proj-button-image {
 
.proj-button:hover .proj-button-image {
 +
  opacity: 0.3;
 +
}
 +
 +
.proj-button:hover .proj-button-image-solo {
 
   opacity: 0.3;
 
   opacity: 0.3;
 
}
 
}
Line 71: Line 89:
  
 
.text {
 
.text {
−
   background-color: honeydew;
+
   background-color: transparent;
 
   color: black;
 
   color: black;
−
   font-size: 16px;
+
   font-size: 20px;
 
   padding: 16px 32px;
 
   padding: 16px 32px;
 
}
 
}
  
−
@media (max-width: 880px) {
+
.paragraph-left {
−
.proj-button-image {
+
  font-family: 'objektiv-mk1' !important;
−
  opacity: 1;
+
  font-size: 18px;
−
  display: inline-block;
+
  text-align: left;
−
  width: 50%;
+
  vertical-align: middle;
−
  height: auto;
+
}
−
  transition: .5s ease;
+
−
  backface-visibility: hidden;
+
−
  }
+
  
−
  .proj-button-desc {
+
p {
−
  transition: .5s ease;
+
  font-family: 'objektiv-mk1' !important;
−
  opacity: 1;
+
/*  margin-left: 200px !important;
−
  position: absolute;
+
  margin-right: 200px !important;*/
−
  top: 100%;
+
  font-size: large !important;
−
  left: 50%;
+
−
  transform: translate(-50%, -50%);
+
−
  -ms-transform: translate(-50%, -50%)
+
−
}
+
 
}
 
}
  
 +
.firstword {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 65px;
 +
}
 +
.quote {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-style: italic !important;
 +
  font-size: 28px;
 +
  line-height: 130%;
 +
}
  
−
</style>
+
.quote-person {
 +
  font-family: 'objektiv-mk1' !important;
 +
  font-size: 22px;
 +
  width: 100% !important;
 +
  text-align: right !important;
 +
  padding-right: 80px !important;
 +
}
  
 +
.titleimg {
 +
  vertical-align: middle;
 +
  width: 15%;
 +
}
 +
 +
.titlebox {
 +
  margin-left: 0px !important;
 +
}
 +
 +
.reference-list {
 +
  font-family: 'objektiv-mk1';
 +
  font-size: 12px;
 +
  text-align: left;
 +
  list-style-type: none;
 +
  line-height: 100%;
 +
  margin-bottom: 80px;
 +
}
 +
 +
.reference-italic {
 +
  font-family: 'objektiv-mk1';
 +
  font-size: 12px;
 +
  font-style: italic;
 +
}
 +
 +
figcaption {
 +
  font-family: 'objektiv-mk1';
 +
  font-style: italic;
 +
  font-size: 13px;
 +
}
 +
 +
 +
@media (min-width: 1144px) {
 +
  .container {
 +
      width: 80% !important;
 +
    }
 +
 +
  .text-container {
 +
    width: 60%;
 +
    padding-left: 30px;
 +
    padding-right: 30px;
 +
  }
 +
 +
  .titlebox {
 +
    width: 80%;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 16px;
 +
  }
 +
}
 +
 +
@media (max-width: 1144px) {
 +
 +
    .titlebox {
 +
      margin-left: auto !important;
 +
    }
 +
 +
  p {
 +
    font-family: 'objektiv-mk1' !important;
 +
    margin-left: 10px !important;
 +
    margin-right: 10px !important;
 +
    font-size: medium !important;
 +
  }
 +
 
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 26px;
 +
  }
 +
 +
  .quote-person {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 20px;
 +
    width: 100%;
 +
    text-align: right;
 +
    padding-right: 80px !important;
 +
  }
 +
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 100%;
 +
  }
 +
 +
  .container {
 +
    width: 70% !important;
 +
    padding-left: 0px !important;
 +
    padding-right: 0px !important;
 +
  }
 +
 +
  .text-container {
 +
    width: 80%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 14px;
 +
  }
 +
}
 +
 +
@media (max-width: 992px) {
 +
  .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 30%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
}
 +
 +
@media (max-width: 768px) {
 +
  .proj-button-image {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 32%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 35%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 +
    .proj-button-desc {
 +
      transition: .5s ease;
 +
      opacity: 0;
 +
      position: absolute;
 +
      top: 100%;
 +
      left: 50%;
 +
      transform: translate(-50%, -50%);
 +
      -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
  .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.0);
 +
    border-radius: 60px;
 +
    color: white;
 +
  }
 +
 +
  h1 {
 +
      font-family: 'objektiv-mk1'; /*!important*/
 +
      font-size: 220%; /*!important*/
 +
      width: 80%;
 +
  }
 +
 +
    h2 {
 +
      font-family: 'objektiv-mk1'; /*!important*/
 +
      font-size: 20px; /*!important*/
 +
  }
 +
 
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 20px;
 +
  }
 +
 +
  .quote-person {
 +
    width: 100%;
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 16px;
 +
    text-align: right !important;
 +
    padding-right: 20px !important;
 +
  }
 +
 +
  .text-container {
 +
    width: 82%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 14px;
 +
    line-height: 140%;
 +
  }
 +
 +
  .reference-list {
 +
    font-family: 'objektiv-mk1';
 +
    font-size: 12px;
 +
    text-align: left;
 +
    list-style-type: none;
 +
    line-height: 100%;
 +
    margin-bottom: 80px;
 +
    margin-right: -70px;
 +
    margin-left: -70px;
 +
  }
 +
}
 +
/*  p {
 +
    margin-left: 10px !important;
 +
    margin-right: 10px !important;
 +
  }
 +
}*/
 +
 +
@media (max-width: 576px) {
 +
  .proj-button-image {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 50%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 +
    .proj-button-image-solo {
 +
      opacity: 1;
 +
      display: inline-block;
 +
      width: 50%;
 +
      height: auto;
 +
      transition: .5s ease;
 +
      backface-visibility: hidden;
 +
    }
 +
 +
    .proj-button-desc {
 +
      transition: .5s ease;
 +
      opacity: 0;
 +
      position: absolute;
 +
      top: 100%;
 +
      left: 50%;
 +
      transform: translate(-50%, -50%);
 +
      -ms-transform: translate(-50%, -50%)
 +
  }
 +
 +
    .overlap-button-text {
 +
    background-color: rgba(94, 94, 94, 0.0);
 +
    border-radius: 60px;
 +
    color: white;
 +
    font-size: 12px;
 +
  }
 +
 +
  .firstword {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 40px;
 +
  }
 +
 +
  .titleimg {
 +
    vertical-align: middle;
 +
    width: 40%;
 +
  }
 +
 +
  p {
 +
    font-family: 'objektiv-mk1' !important;
 +
    margin-left: 10px !important;
 +
    margin-right: 10px !important;
 +
    font-size: small !important;
 +
  }
 +
 +
  h1 {
 +
    font-size: 160%;
 +
  }
 +
 +
  .quote {
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-style: italic !important;
 +
    font-size: 17px;
 +
  }
 +
 +
  .quote-person {
 +
    width: 60% !important;
 +
    font-family: 'objektiv-mk1' !important;
 +
    font-size: 12px;
 +
    text-align: right !important;
 +
    margin-right: -120px !important;
 +
  }
 +
 +
  .paragraph-left {
 +
    font-size: 13px;
 +
    line-height: 170%;
 +
  }
 +
 +
  .text-container {
 +
    width: 85%;
 +
    padding-left: 0px;
 +
    padding-right: 0px;
 +
  }
 +
 +
  .metabolic-pathway {
 +
      margin: auto;
 +
      background: honeydew;
 +
      width: 110%;
 +
      margin-left: -20px;
 +
      margin-right: -20px;
 +
  }
 +
 +
  figcaption {
 +
    font-size: 12px;
 +
    line-height: 130%;
 +
  }
 +
 +
  .reference-list {
 +
    font-family: 'objektiv-mk1';
 +
    font-size: 12px;
 +
    text-align: left;
 +
    list-style-type: none;
 +
    line-height: 100%;
 +
    margin-bottom: 80px;
 +
    margin-right: -50px;
 +
    margin-left: -50px;
 +
  }
 +
}
 +
 +
@media (max-width: 400px) {
 +
  .quote {
 +
    font-size: 15px;
 +
  }
 +
}
 +
 +
 +
</style>
  
 
<body>
 
<body>
 
<div id="page">
 
<div id="page">
 
<center>
 
<center>
−
  <div class="pageflow">
+
<br>
−
<img src="https://static.igem.org/mediawiki/2017/b/bf/Project_desc.png" style="user-drag:none;
+
−
user-select: none;
+
−
-moz-user-select: none;
+
−
-webkit-user-drag: none;
+
−
-webkit-user-select: none;
+
−
-ms-user-select: none;
+
−
        width: 80%;">
+
−
+
−
</div>
+
  
−
<h1>Click on an icon below to learn more about our project!</h1>
+
<!--<div class="titlebox">
 +
    <div class="row no-gutters justify-content-md-center">
 +
      <div class="col-sm-4">
 +
        <center>
 +
          <img class="buddies" src="https://static.igem.org/mediawiki/2017/f/f9/3synechobuddies.png">
 +
        </center>
 +
      </div>
 +
      <div class="col-md-6">
 +
        <h1>PROJECT DESCRIPTION</h1>
 +
      </div>
 +
    </div>
 +
</div>-->
  
−
<div class="row">
+
<center><img class='titleimg' src="https://static.igem.org/mediawiki/2017/3/36/Projectimg.png"></center>
−
<a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button">
+
<h1>PROJECT DESCRIPTION</h1><br>
−
  <img src="https://static.igem.org/mediawiki/2017/7/74/Ace_icon.png" class="proj-button-image">
+
−
  <div class="proj-button-desc">
+
−
    <div class="text">Acetaminophen</div>
+
−
  </div>
+
−
</a>
+
  
−
<a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button">
+
<br>
−
  <img src="https://static.igem.org/mediawiki/2017/1/19/B12_icon.png" class="proj-button-image">
+
<br>
−
  <div class="proj-button-desc">
+
−
    <div class="text">Vitamin B-12</div>
+
−
  </div>
+
−
</a>
+
  
−
<a href="https://2017.igem.org/Team:UCSC/Bioreactor" class="proj-button">
+
  <!--<div class="container">
−
  <img src="https://static.igem.org/mediawiki/2017/c/c4/Bioreactor_icon.png" class="proj-button-image">
+
    <p><span class="firstword">We </span>are using the cyanobacteria genus Synechococcus as a model for the FDA-approved Arthrospira platensis, commonly known as Spirulina. By focusing on an edible cyanobacteria, we hope to generate an easily consumable, photosynthetic culture of vitamin or pharmaceutical synthesizers.</p>
−
  <div class="proj-button-desc">
+
<br>
−
    <div class="text">Bioreactor</div>
+
    <p>Of the three non-opioid pain reducers on the World Health Organization’s (WHO) list of essential medicines, we have decided to pursue acetaminophen, the active ingredient in Tylenol, due to the feasibility of recreating the metabolic pathway in a cyanobacteria. With respect to vitamins, we aim to produce human usable vitamin B12 because it is one of the few vitamins that A. platensis does not adequately produce.</p>
−
  </div>
+
  </div>-->
−
</a>
+
  
−
<a href="https://2017.igem.org/Team:UCSC/Modeling" class="proj-button">
+
  <div class="text-container">
−
  <img src="https://static.igem.org/mediawiki/2017/d/d8/Modeling_icon.png" class="proj-button-image">
+
    <p><span class="firstword">Malnutrition</span> and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions<sup>[1]</sup>. Our project, <i>Bugs Without Borders</i>, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, <i>Arthrospira platensis</i>, commonly referred to as Spirulina. <i>A. platensis</i> is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"<sup>[2]</sup>.</p>
−
  <div class="proj-button-desc">
+
−
    <div class="text">Modeling</div>
+
−
  </div>
+
−
</a>
+
  
−
<a href="https://2017.igem.org/Team:UCSC/Results" class="proj-button">
+
    <br>
−
  <img src="https://static.igem.org/mediawiki/2017/e/e6/Results_icon.png" class="proj-button-image">
+
    <br>
−
  <div class="proj-button-desc">
+
−
    <div class="text">Results</div>
+
−
  </div>
+
−
</a>
+
  
 +
    <center>
 +
      <img class="metabolic-pathway" src="https://static.igem.org/mediawiki/2017/5/59/Cyanobuddies.png">
 +
    </center>
 +
 +
    <br>
 +
    <br>
 +
 +
    <p>Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B<sub>12</sub> (the form of vitamin B<sub>12</sub> that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture<sup>[3]</sup>.</p>
 +
 +
    <br>
 +
 +
    <p>The integration and performance of the genes in acetaminophen production, <i>4ABH</i> and <i>nhoA</i>, and those in vitamin DMB B<sub>12</sub> production, <i>ssuE</i> and <i>bluB</i>, were investigated in the model cyanobacteria, <i>Synechococcus elongatus</i> PCC 7942 with the aim of subsequent integration into <i>A. platensis</i> once a genetic system has been studied and established. An <i>in vivo</i> vitamin B<sub>12</sub> detection system was also optimized for <i>S. elongatus</i> and <i>E. coli</i> by altering the ribosome binding site on the B<sub>12</sub> riboswitch (part BBa_K1913011) and the <i>psbAI</i> (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of <i>A. platensis</i> UTEX 2340 to further enable genetic research in this organism and its potential medical applications.</p>
 +
 +
  </div>
 +
 +
<br>
 +
<br>
 +
 +
<h2>Click on an icon below to learn more about our project!</h2>
 +
 +
<div class="row">
 +
  <a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/6/6c/Acetaminophenicon.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">ACETAMINOPHEN</div>
 +
      </div>
 +
  </a>
 +
 +
  <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/a/a2/B12_flask_button.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">VITAMIN B<sub>12</sub></div>
 +
      </div>
 +
  </a>
 +
 +
  <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/b/be/Modeling_button.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">MODELING</div>
 +
      </div>
 +
  </a>
 
</div>
 
</div>
 +
<div class="row">
  
 +
  <a href="https://2017.igem.org/Team:UCSC/Demonstrate" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/a/ad/Resulticon.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">RESULTS</div>
 +
      </div>
 +
  </a>
  
 +
  <a href="https://2017.igem.org/Team:UCSC/Target-Organism" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/8/84/Spirulinaicon.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">TARGET ORGANISM</div>
 +
      </div>
 +
  </a>
 +
 +
  <a href="https://2017.igem.org/Team:UCSC/Part_Collection" class="proj-button">
 +
      <img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image">
 +
      <div class="proj-button-desc">
 +
        <div class="overlap-button-text">PARTS</div>
 +
      </div>
 +
  </a>
 +
 +
<br>
 +
<br>
 +
 +
<div class="container">
 +
    <div class="container">
 +
      <div class="reference-list">
 +
      <hr>
 +
        <li>[1] Taylor, D. W., & CIM, F. (2010). Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes”. Cameron Institute, October.</li>
 +
        <li>[2] Spirulina Benefits: 7 Reasons to Try It (& 1 Major Caution) Wellness Mama. (n.d.). Retrieved October 26, 2017, from https://wellnessmama.com/4738/spirulina-benefits/</li>
 +
        <li>[3] World  Health  Organization, ed., <i>The  Selection  and  Use  of  Essential  Medicines: report  of  the WHO  Expert  Committee,  2007; (including  the  15th  model  list  of  essential  medicines</i>).  No. 946in WHO Technical Report Series, Geneva:  World Health Organization, 2007. OCLC: 254437808.</li>
 +
      </div>
 +
    </div>
 +
  </div>
 +
 +
<br>
 +
<br>
 +
 +
</div>
 
</center>
 
</center>
 
</div>
 
</div>
 
</body>
 
</body>
 
</html>
 
</html>
−
 
 
{{UCSC-Footer}}
 
{{UCSC-Footer}}

Latest revision as of 02:47, 2 November 2017


PROJECT DESCRIPTION




Malnutrition and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions[1]. Our project, Bugs Without Borders, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, Arthrospira platensis, commonly referred to as Spirulina. A. platensis is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"[2].





Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B12 (the form of vitamin B12 that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture[3].


The integration and performance of the genes in acetaminophen production, 4ABH and nhoA, and those in vitamin DMB B12 production, ssuE and bluB, were investigated in the model cyanobacteria, Synechococcus elongatus PCC 7942 with the aim of subsequent integration into A. platensis once a genetic system has been studied and established. An in vivo vitamin B12 detection system was also optimized for S. elongatus and E. coli by altering the ribosome binding site on the B12 riboswitch (part BBa_K1913011) and the psbAI (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of A. platensis UTEX 2340 to further enable genetic research in this organism and its potential medical applications.



Click on an icon below to learn more about our project!

ACETAMINOPHEN
VITAMIN B12
MODELING
RESULTS
TARGET ORGANISM
PARTS

  • [1] Taylor, D. W., & CIM, F. (2010). Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes”. Cameron Institute, October.
  • [2] Spirulina Benefits: 7 Reasons to Try It (& 1 Major Caution) Wellness Mama. (n.d.). Retrieved October 26, 2017, from https://wellnessmama.com/4738/spirulina-benefits/
  • [3] World Health Organization, ed., The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007; (including the 15th model list of essential medicines). No. 946in WHO Technical Report Series, Geneva: World Health Organization, 2007. OCLC: 254437808.


    • S P O N S O R S
    S O C I A L
    C O N T A C T
    Jack Baskin School of Engineering
    University of California, Santa Cruz
    1156 High Street
    Santa Cruz, California, 95064